The agreement follows the European Commission’s decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced Purchase Agreement signed on February 17.
With this, the total number of doses to be delivered to the EU would be 600 million. COMIRNATY will be produced in BioNTech’s and Pfizer’s manufacturing sites in Europe.
The companies said they plan to deliver 250 million doses to the EU in the second quarter, a fourfold increase on first quarter’s agreed quantity.
Sean Marett, Chief Business and Chief Commercial Officer of BioNTech, said, “The additional 100 million doses from this option exercise will further help to support the acceleration of the vaccination campaigns throughout the EU. We now intend to deliver a total of 600 million doses to the EU this year, which covers two thirds of the EU population and represents the largest cumulative supply agreement for COMIRNATY that we have agreed to date globally.”
For comments and feedback contact: [email protected]